BioNTech CEO Sierk Pötting believes that the company is on track with the development of the SARS-CoV-2 vaccine candidate BNT162. The safety profile looks good, said Pötting at the Finance Day 2020 of GoingPublic and Platform Life Sciences.
So far, there have been no reportable security incidents. However, the ongoing clinical study is not yet at an end, according to the CFO & COO of the Mainz-based biotech company, which is now listed on the stock exchange in the double-digit billions. BioNTech‘s shares are listed on the primary stock exchange NASDAQ, among others, but can also be traded on German stock markets.
If you want to find more details about BioNTech and when its vaccine against COVID-19 will be released on the market, download for free the Born2Invest mobile app. Our companion app brings you the latest breakthroughs in the biotech sector and the most important financial headlines in the world, so you can stay informed.
When will the first data about the COVID-19 vaccine be presented
Pötting expects to be able to present the first data from the ongoing study on the efficacy of BNT162 at the end of October or beginning of November. In previous studies, the vaccine has already provided promising immunity data and, together with Moderna’s vaccine candidate, is considered to be the most promising and advanced vaccine project against the pathogen of the corona pandemic, the SARS-CoV-2 virus.
BioNTech and marketing partner Pfizer are currently building up production capacities for BNT162. Pfizer CEO Albert Bourla announced on Friday that the vaccine could be submitted for approval in the USA in the third week of November.
The prerequisite is that both the clinical trial and the production facilities meet the requirements for an application for approval. “First, the vaccine must be proven to be effective, i.e. it can help prevent COVID-19 disease in at least the majority of vaccinated patients. Second, and equally important, the vaccine must have been proven safe, with robust safety data from thousands of patients. And finally, we must prove that the vaccine can be consistently produced to the highest quality standards,” the Pfizer CEO said in the open letter on Friday – we reported.
BioNTech stock: The fronts are hardening
BioNTech’s shares rose 0.46 percent to $94.35 on a closing price basis on the NASDAQ yesterday, October 20th. However, that sounds more boring than the charts ultimately showed for the biotech stock. Share prices for the bearer of hope in the fight against the Corona pandemic ranged between $91.61 and $96.12. That means that the share price of the Mainz-based company was able to successfully defend itself against new sell signals on the charts, which could exert pressure after the recent rally.
At the same time, however, there was no breakthrough upwards towards an all-time high of $105. The technical fronts are thus hardening, and the signal marks for the BioNTech share have not changed. The central resistance level on the charts is currently $96.09/$97.82. Although this came into view last week, “real” tests were only carried out on Monday with a daily high at $97.29 and yesterday, October 20th. Both tests had no success.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in 4investors, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Which of these lesser-known EV stocks will be the next Tesla?
The competition on the EV market is getting tighter, as several lesser known manufacturers are raising the interest of investors....
Gigantic cannabis plantation officially opened in Northern Macedonia
In addition to the cannabis plantation, PHCANN - which is also listed on the New York Stock Exchange - has...
Is the Ethereum 2.0 deadline bullish for the ETH course?
With the launch of Ethereum 2.0, a new era could begin for the young Decentralized Finance (DeFi) industry. The change...
Exit for an SME financed with equity crowdfunding: Cesynt shares on Euronext
Founded in 2010, Cesynt had already conducted a first equity crowdfunding campaign on Opstart in June 2018, collecting $297,000 (€250,000),...
The business environment in Morocco: the EESC calls for more effort
In its annual report, published in the Official Gazette on November 17th, 2020, the Economic, Social and Environmental Council in...
Cannabis7 days ago
CBOS survey: over 60% of Poles are for cannabis legalization
Biotech7 days ago
Ability Pharma closes €2 million round to advance antitumor development
Featured7 days ago
Moneyfarm launches smart bank transfer to invest directly from the current accounts of multiple banks
Featured7 days ago
How to generate performance through responsible investments